The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: A systematic review and meta-analysis

Diabetes and Vascular Disease Research

Volumn 7, Issue 2, 2010, Pages 119-130

  Marso, Steven P ^a   Kennedy, Kevin F ^a   House, John A ^a   McGuire, Darren K ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Diabetes mellitus; Glucose lowering; MACE; Macrovascular complications; Mortality; Myocardial infarction; Stroke

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN DERIVATIVE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL RESEARCH; CLINICAL TRIAL; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; STROKE; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 77954478975     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109353367     Document Type: Article

References (30)

1. National Diabetes Fact Sheet 2007. Washington DC: US Department of Health and Human Services, 2007.
2. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. Jama 290: 1884-90.
3. Grundy SM, Cleeman JI, Merz CN, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-39.
4. Buse JB, Ginsberg HN, Bakris GL, et al. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30: 162-72.
5. Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2: 120-6.
6. Fox CS, Coady S, Sorlie PD, et al. (2004) Trends in cardiovascular complications of diabetes. Jama 292: 2495-9.
7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-93.
8. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-53.
9. Duckworth W, Abraira C, Moritz T, et al. (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-39.
10. Gerstein HC, Miller ME, Byington RP, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-59.
11. Patel A, MacMahon S, Chalmers J, et al. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-72.
12. National Library of Medicine PubMed database http://www.ncbi.nlm.nih.gov/ pubmed/
13. Cochrane Central Register for Controlled Trials http://mrw.interscience. wiley.com/cochrane/cochrane-clcentral-articles-fs.html
14. Cochrane Database for Systematic Reviews http://www.cochrane.org/reviews
15. ClinicalTrials.gov http://www.clinicaltrials.gov
16. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-65.
17. Abraira C, Colwell J, Nuttall F, et al. (1997) Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 157: 181-8.
18. Stettier C, Allemann S, Juni P, et al. (2006) Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152(1): 27-38.
19. Sutton A, Abrams K, Jones D, Sheldon T, Song F. Methods for Meta-Analysis in Medical Research. Chichester, UK: John Wiley & Sons, 2002.
20. Ray KK, Seshasai SR, Wijesuriya S, et al. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765-72.
21. Dormandy JA, Charbonnel B, Eckland DJ, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-89.
22. Home PD, Pocock SJ, Beck-Nielsen H, et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357(1): 28-38.
23. Diamond GA, Bax L, Kaul S (2007) Uncertain effects of ros- iglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 147: 578-81.
24. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-71.
25. Skyler JS, Bergenstal R, Bonow RO, et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53: 298-304.
26. McGuire DK, Inzucchi SE (2008) New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 117: 440-49.
27. Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. Jama 294: 2581-6.
28. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. Washington DC: US Department of Health and Human Services, 2008.
29. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-89.
30. Abbey DM (2009) Earlier treatment may explain diabetes data. Science 323: 1009.